San Antonio, Texas
Cancer clinical trials in San Antonio, TX
195 cancer studies are recruiting participants at sites in San Antonio as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
San Antonio at a glance
- 195 studies are recruiting at a site in San Antonio.
- By phase: Phase 1 (68), Phase 1/2 (48), Phase 2 (19), Phase 2/3 (2), Phase 3 (37), No phase (7), Observational (14). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (156), university, hospital or other (33), government (6).
- By research area: Breast Cancer (78), Lung Cancer (51), Lymphoma (33), Prostate Cancer (17), Pancreatic Cancer (11), Melanoma (5).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in San Antonio
Basic details from each study's public record (the 30 most recently updated of 195). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Study site
- NEXT Oncology - PARENT
- Registry record
- NCT07360314 · updated
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- START San Antonio (STSA)
- Registry record
- NCT07488676 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Texas Health Science Center at San Antonio
- Registry record
- NCT06058377 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- UT Health San Antonio's Mays Cancer Center
- Registry record
- NCT06270706 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study sites
- START San Antonio, LLC · University of Texas Health Science Center San Antonio
- Registry record
- NCT06638307 · updated
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- South Texas Accelerated Research Therapeutics (START), LLC
- Registry record
- NCT06827236 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8001)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8004)
- Registry record
- NCT06966700 · updated
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study sites
- NEXT Texas LLC - San Antonio · START San Antonio, LLC
- Registry record
- NCT07503808 · updated
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Immunomic Therapeutics, Inc.
- Study site
- START San Antonio
- Registry record
- NCT07652242 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mays Cancer Center ( Site 0122)
- Registry record
- NCT06393374 · updated
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- South Texas Accelerated Research Therapeutics (START) San Antonio
- Registry record
- NCT07029399 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Lung cancer studies recruiting in San Antonio
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Phase 1/2
- Ages 18 to 75
- All sexes
- Sponsor
- Tyligand Pharmaceuticals (Suzhou) Limited
- Study site
- NEXT Oncology
- Registry record
- NCT06385925 · updated
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- START San Antonio, LLC
- Registry record
- NCT07903415 · updated
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- NEXT Oncology
- Registry record
- NCT03460977 · updated
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- START | San Antonio
- Registry record
- NCT06914128 · updated
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- START- San Antonio
- Registry record
- NCT07080242 · updated
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- No phase
- Ages 50 to 80
- All sexes
- Sponsor
- bioAffinity Technologies Inc.
- Study sites
- Audie Murphy VA Medical Center · Brooke Army Medical Center
- Registry record
- NCT07168993 · updated
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Kestrel Therapeutics, Inc.
- Study site
- NEXT Oncology
- Registry record
- NCT07458347 · updated
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Texas Oncology - San Antonio
- Registry record
- NCT07680790 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Lymphoma studies recruiting in San Antonio
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- M.D. Anderson Cancer Center
- Study site
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
- Registry record
- NCT05676450 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Methodist Children's Hospital
- Registry record
- NCT06173518 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Texas Oncology - San Antonio ( Site 8009)
- Registry record
- NCT06890884 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Children's Hospital of San Antonio · Methodist Children's Hospital of South Texas · University of Texas Health Science Center at San Antonio
- Registry record
- NCT05675410 · updated
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Phase 1/2
- Up to age 1
- All sexes
- Sponsor
- Tanja Andrea Gruber
- Study site
- University of Texas Health Science Center San Antonio
- Registry record
- NCT05848687 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Texas Health Science Center at San Antonio
- Registry record
- NCT06337318 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Antonio, TX on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in San Antonio
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US063 · Investigative Site US080
- Registry record
- NCT07522073 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- START- San Antonio
- Registry record
- NCT07644559 · updated
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immuneering Corporation
- Study site
- Texas Oncology - San Antonio
- Registry record
- NCT07562152 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Antonio, TX on ClinicalTrials.gov.
Ask about studies near San Antonio
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Texas
All Texas locations
894 studies recruiting across 75 cities.
Houston
624 studies recruiting.
Dallas
243 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections